Gleevec Decreases Cancer Recurrence for Patients with a Type of Gastrointestinal Cancer

New York

on Thursday, April 12, 2007

Memorial Sloan Kettering Cancer Center’s Ronald DeMatteo, MD, served as the principal investigator of a large cooperative group trial that found patients with primary gastrointestinal stromal tumor, a type of tumor found in the stomach or small intestine, who received imatinib (Gleevec ®) after complete removal of their tumor were significantly less likely to have a recurrence of the cancer compared to those who did not receive imatinib.

For more information about this National Cancer Institute funded study, go to:

Journalists may contact the Department of Public Affairs for more information.

Telephone: 212-639-3573